Compare Core Scientific Inc (CORZ) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Core Scientific Inc vs Smith & Nephew plc — how do they compare? Core Scientific Inc trades at $15.41 (market cap $4.94B), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 2.2× Core Scientific Inc's market cap, and Smith & Nephew plc pays a 2.95% dividend while Core Scientific Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Core Scientific Inc for 20 Days and Smith & Nephew plc for 121 Days on average.
| CORZ | SNN | |
|---|---|---|
Market Cap | $4.94B | $11.10B |
Volume | 15,630,800 | 1,051,703 |
Sector | Technology | Health |
52-Week High | $29.16 | $37.17 |
52-Week Low | $13.57 | $26.42 |
Typical Hold Time | 20 Days | 121 Days |
Enterprise Value | $7.46B | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Core Scientific (CORZ) trades at $15.36, down 3.64% on the day, with bearish technical signals and negative earnings momentum. The company reported a net loss of $288.62 million in 2025 with revenue of $319.02 million, resulting in a -324.9% net income margin. Despite financial challenges, analyst sentiment remains overwhelmingly positive with 19 buy ratings and a $32.75 consensus price target, representing significant upside potential from current levels.
The stock presents a high-risk, high-reward opportunity with strong Wall Street support but substantial fundamental challenges. Positive catalysts include the AI data center transition and insider buying, while risks include persistent losses, heavy capital expenditures, and competitive pressures in the digital infrastructure space.
SNN trades at $26.96, up 0.26% on the day, but near its 52-week low amid a bearish technical signal. Recent earnings have mostly beaten expectations, with Q2 2026 EPS of $0.946 exceeding the $0.939 estimate. Revenue grew to $6.16B in 2025, and net income margin improved to 10.08%. The company continues to launch new medical products, such as the EVOS PELVIC System, to drive growth.
The outlook is mixed; strong fundamentals and product innovation support long-term value, but near-term price pressure and analyst caution pose risks. Investors should weigh robust profitability against competitive threats and recent management changes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Core Scientific Inc
Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.
Read more on CORZ →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
